Telix (ASX:TLX) has released further details of the positive results from its completed pivotal Phase 3 ZIRCON study of TLX250-CDx in clear cell renal cell carcinoma (ccRCC).
The company said the new data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting, and for staging and informing treatment decisions.
"TLX250-CDx PET/CT detected more lesions in liver and bone than diagnostic CT imaging alone," said the company, adding, "This reinforces the performance of this investigational diagnostic imaging agent across all analyses, with previously presented data showing an excellent overall sensitivity and specificity of 86% and 87%, respectively, together with high intra-reader agreement."